Literature DB >> 29410490

MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts.

Yuki Togashi1,2,3, Akito Dobashi1, Seiji Sakata1, Yukiko Sato2, Satoko Baba1, Akira Seto4, Hiroki Mitani4, Kazuyoshi Kawabata4, Kengo Takeuchi5,6,7.   

Abstract

MYB-NFIB and MYBL1-NFIB have been reported in ~60% of adenoid cystic carcinoma cases, but driver alterations in the remaining ~40% of adenoid cystic carcinoma remain unclear. We examined 100 adenoid cystic carcinoma cases for MYB and MYBL1 locus rearrangements by fluorescence in situ hybridization (FISH) with originally designed probe sets using formalin-fixed paraffin-embedded materials. Approximately one-third of samples were also analyzed by fusion transcript-specific RT-PCR and capture RNA sequencing. In the 27 cases with frozen materials, MYB-NFIB and MYBL1-NFIB fusion transcripts were detected in 9 (33%) and 6 cases (22%) by RT-PCR, respectively. Meanwhile, high expression of MYB (18 cases, 67%) or MYBL1 (9 cases, 33%) was detected in all 27 cases in a mutually exclusive manner, regardless of its form (full-length, truncation, or fusion transcript). Interestingly, genomic rearrangements around the corresponding highly-expressed gene were observed in all 27 cases by FISH, suggesting a causative relationship between genomic rearrangements and gene expression. Among the 100 cases, including additional 73 cases, 97 harbored genomic rearrangements in the MYB (73 cases) or MYBL1 locus (24 cases) including 10 cases with atypical FISH patterns undetectable through ordinary split FISH approaches: breakpoints far distant from MYB (5 cases) and a small NFIB locus insertion into the MYB (3 cases) or MYBL1 locus (2 cases). In clinicopathological analyses, histological grade, primary tumor size, and lymph node metastasis were identified as prognostic factors, whereas MYB/MYBL1 rearrangements were not, but were associated with histological grade. In the present study, MYB or MYBL1 locus rearrangement was detected in nearly all adenoid cystic carcinoma cases, and therefore it would be a good diagnostic marker for adenoid cystic carcinoma. However, fusion transcript-specific RT-PCR for MYB-NFIB and MYBL1-NFIB and ordinary split FISH assays for MYB and MYBL1 were less sensitive, and thus detection methods should be judiciously designed because of the diversity of rearrangement modes in adenoid cystic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29410490     DOI: 10.1038/s41379-018-0008-8

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  23 in total

Review 1.  [Salivary gland tumors-an overview : Advances in molecular characterization: Part I].

Authors:  Niels J Rupp; Sandra N Freiberger
Journal:  Pathologie (Heidelb)       Date:  2022-10-13

2.  Possible Relationship Between MYBL1 Alterations and Specific Primary Sites in Adenoid Cystic Carcinoma: A Clinicopathological and Molecular Study of 36 Cases.

Authors:  Yukari Endo; Satoshi Kuwamoto; Takahito Ohira; Michiko Matsushita; Takahiro Matsushige; Takahiro Fukuhara; Shu Nakamoto; Kazuhiko Hayashi; Hiroyuki Kugoh; Yasuaki Hirooka
Journal:  Yonago Acta Med       Date:  2019-03-28       Impact factor: 1.641

Review 3.  Pleomorphic Adenoma of External Auditory Canal: Case Report of First Endoscopic Resection and Literature Review.

Authors:  Sven Beckmann; Matthias S Dettmer; Marco D Caversaccio; Roland Giger; Lukas Anschuetz
Journal:  Medicina (Kaunas)       Date:  2020-05-20       Impact factor: 2.430

4.  Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma.

Authors:  Julia Thierauf; Nisha Ramamurthy; Vickie Y Jo; Hayley Robinson; Ryan P Frazier; Jonathan Gonzalez; Maciej Pacula; Enrique Dominguez Meneses; Vania Nose; Valentina Nardi; Dora Dias-Santagata; Long P Le; Derrick T Lin; William C Faquin; Lori J Wirth; Jochen Hess; A John Iafrate; Jochen K Lennerz
Journal:  Oncologist       Date:  2019-03-29

5.  Detecting MYB and MYBL1 fusion genes in tracheobronchial adenoid cystic carcinoma by targeted RNA-sequencing.

Authors:  Jianming Pei; Douglas B Flieder; Arthur Patchefsky; Jacqueline N Talarchek; Harry S Cooper; Joseph R Testa; Shuanzeng Wei
Journal:  Mod Pathol       Date:  2019-04-25       Impact factor: 7.842

6.  SS18 Break-Apart Fluorescence In Situ Hybridization is a Practical and Effective Method for Diagnosing Microsecretory Adenocarcinoma of Salivary Glands.

Authors:  Justin A Bishop; Prasad Koduru; Brandon M Veremis; Bahram R Oliai; Ilan Weinreb; Lisa M Rooper; Brendan C Dickson; Elizabeth G Demicco
Journal:  Head Neck Pathol       Date:  2021-01-04

Review 7.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

8.  Genetic profiling of patients with adenoid cystic carcinoma of the Bartholin's glands reveals potential new routes for targeted therapies: a case report.

Authors:  Kohei Nakamura; Eriko Aimono; Shigeki Tanishima; Hidetaka Nomura; Mitsuho Imai; Hideyuki Hayashi; Hiroshi Nishihara
Journal:  Diagn Pathol       Date:  2020-05-28       Impact factor: 2.644

9.  Weighted Gene Coexpression Network Analysis to Construct Competitive Endogenous RNA Network in Chromogenic Renal Cell Carcinoma.

Authors:  Yong-Bo Chen; Liang Gao; Jin-Dong Zhang; Jiang Guo; Ping-Hong You; Liang-You Tang; Ying-Wen Liu
Journal:  Biomed Res Int       Date:  2021-06-10       Impact factor: 3.411

10.  Targeted RNA sequencing in the routine clinical detection of fusion genes in salivary gland tumors.

Authors:  Justin Bubola; Christina M MacMillan; Elizabeth G Demicco; Rose A Chami; Catherine T-S Chung; Iona Leong; Paula Marrano; Zeynep Onkal; David Swanson; Brandon M Veremis; Ilan Weinreb; Lei Zhang; Cristina R Antonescu; Brendan C Dickson
Journal:  Genes Chromosomes Cancer       Date:  2021-07-08       Impact factor: 4.263

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.